<a href="https://www.fiercebiotech.com/biotech/gilead-loosens-ties-arcus-after-tigit-dream-finally-ends-phase-3-failure" hreflang="en">Gilead loosens ties to Arcus after TIGIT dream finally ends in phase 3 failure</a>
Gilead Sciences has ended its collaboration with Arcus Biosciences following the failure of their anti-TIGIT antibody, domvanalimab, in a phase 3 trial for non-small cell lung cancer, leading Gilead to relinquish options on several early-stage programs while retaining rights to some clinical-stage candidates. This decision reflects a broader trend in the biotech industry as many companies abandon TIGIT-targeting therapies after a series of clinical failures.
The key insight for someone interested in healthtech and biotech is that Gilead Sciences' decision to loosen ties with Arcus Biosciences after the phase 3 failure of their anti-TIGIT antibody, domvanalimab, signals a strategic pivot away from TIGIT-based therapies due to repeated clinical setbacks. This development suggests an opportunity to scrutinize other immuno-oncology targets and highlights the importance of reassessing investment strategies in emerging biotech collaborations, particularly in the context of immune checkpoint inhibitors.